Auspex Pharmaceuticals, Inc. (ASPX) [Rocket]

In millions, except per share items	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11
	10-K	10-K	10-K	10-K
Revenues [+]	0.0	-0.3	-0.2	4.1
Net interest income		-0.3	-0.2
Revenue growth	-100.0%	31.6%	-104.8%
Cost of goods sold	0.0	-26.4	-26.9	6.0
Gross profit	0.0	26.1	26.7	-1.9
Gross margin		-10126.4%	-13603.1%	-46.4%
Selling, general and administrative [+]	12.5	3.2	1.7	1.9
General and administrative	12.5	3.2	1.7	1.9
Research and development	37.7	10.0	11.7
Other operating expenses	-3.6	24.2	26.7	-4.0
EBITDA [+]	-46.6	-11.2	-13.4	0.4
EBITDA growth	314.0%	-16.0%	-3821.9%
EBITDA margin		4360.1%	6836.2%	8.8%
Depreciation and amortization	0.0	0.0	0.0	0.2
EBIT [+]	-46.6	-11.3	-13.4	0.2
EBIT growth	314.0%	-16.1%	-6848.2%
EBIT margin		4364.7%	6851.5%	4.9%
Non-recurring items	3.6	1.9		3.1
Interest expense, net [+]	1.4	0.2	1.3	0.0
Interest expense	2.6	0.2	1.3	0.0
Interest income	1.2		0.0
Other income (expense), net [+]	-7.9	-2.2	-0.4	0.1
Change in fair value of warrants	-3.6	-1.9	-0.2
Other	0.1	-2.4	-1.7
Pre-tax income	-59.5	-15.6	-15.1	-2.8
Income taxes	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%
Minority interest	0.0
Net income	-59.6	-15.6	-15.1	-2.8
Net margin		6057.8%	7710.2%	-69.0%

Basic EPS [+]	($2.68)	($371.13)	($114,484.85)	($21,318.18)
Growth	-99.3%	-99.7%	437.0%
Diluted EPS [+]	($2.68)	($371.13)	($114,484.85)	($21,318.18)
Growth	-99.3%	-99.7%	437.0%

Shares outstanding (basic) [+]	22.2	0.0	0.0	0.0
Growth	52605.9%	31803.0%	0.0%
Shares outstanding (diluted) [+]	22.2	0.0	0.0	0.0
Growth	52605.9%	31803.0%	0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.